United Neuroscience to Present Alzheimer’s Vaccine Clinical Trial Update at CTAD 2018
Lead Program on Track for Phase IIa Clinical Data Announcement Before Year-End
United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, announced that the company will present a clinical trial update for its lead vaccine candidate, UB-311, at the International Conference on Clinical Trials for Alzheimer’s Disease (CTAD), which takes place Oct. 24-27 in Barcelona. CTAD’s goal is to bring together leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics and procedural issues to help develop the next generation of Alzheimer’s disease treatments.
“We are highly encouraged by the progress of our Alzheimer’s vaccine program and remain on track to announce top-line data from our Phase IIa study before the end of the year,” said Mei Mei Hu, Chief Executive Officer of United Neuroscience. “Alzheimer’s disease is one of the greatest challenges in the world of medicine, and United Neuroscience is committed to developing innovative technologies for this growing patient population.”
Ajay Verma, M.D., Ph.D., the company’s Chief Medical Officer, added, “We are eager to examine the anti-Aβ antibody response elicited by the different boosting schedules in our Phase IIa study. The multiple brain MRI and amyloid PET scans included in our study will help us to objectively assess safety and target engagement.”